Table 4.
Switching patterns of anchor drug class in ART regimens by switching timing from 2011 to 2016
| Timing of switch (n = 268) | Anchor drug class in the second regimen | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Switch < 1 year after starting the first regimen | Switch ≥1 year after starting the first regimen | |||||||||||||||||
| Anchor drug class in the first regimen | NNRTI | PI | INSTI | NNRTI | PI | INSTI | ||||||||||||
| n | % | (95% CIa) | n | % | (95% CIa) | n | % | (95% CIa) | n | % | (95% CIa) | n | % | (95% CIa) | n | % | (95% CIa) | |
| NNRTI | – | – | – | 4 | 8.3 | (3.3–19.6) | 44 | 91.7 | (80.4–96.7) | – | – | – | 0 | 0.0 | – | 35 | 100.0 | (90.1–100.0) |
| PI | 2 | 2.5 | (0.7–8.6) | – | – | – | 79 | 97.5 | (91.4–99.3) | 2 | 2.5 | (0.7–8.6) | – | – | – | 79 | 97.5 | (91.4–99.3) |
| INSTI | 5 | 35.7 | (16.3–61.2) | 8 | 57.1 | (32.6–78.6) | – | – | – | 4 | 50.0 | (21.5–78.5) | 4 | 50.0 | (21.5–78.5) | – | – | – |
ART antiretroviral therapy, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, INSTI integrase strand transfer inhibitor, CI confidence interval
Two patients who had multiple prescription records of anchor drug class in the second regimen were excluded from the analysis
Entry inhibitor was excluded from the table as only two patients were prescribed an entry inhibitor in the first/second ART regimen
aWilson score